GARDP SAC Chair
GARDP
Chapel Hill, NC, United States
Dr. Prabhavathi Fernandes, Ph.D., has more than 35 years of pharmaceutical discovery, development and management experience having held executive leadership positions at pharmaceutical corporations including Bristol-Myers Squibb Pharmaceutical Research Institute, Abbott Laboratories and The Squibb Institute for Medical Research. After leaving Bristol- Myers Squibb, she has founded and led four biotechnology and CRO companies as President, Chief Executive Officer and Director of each of these companies, including Cempra, Inc., DarPharma, Ricerca and Small Molecule Therapeutics. During her years in Pharma she was directly involved with the development of 4 antibiotics for human use and 2 for animal/agricultural use. In 1995, she served on the Technology Assessment Advisory Council on the Impacts of Antibiotic Resistant Bacteria for the US Congress. She is the Chairperson of the National Biodefense Science Board (NBSB) and is Chairperson of the Scientific Advisory Committee of the Global Antibiotic Research and Development Partnership (GARDP), a DNDi/WHO initiative. She is on the WHO clinical antibacterial pipeline advisory group and member of the ACTIV NIH working group for therapeutics and vaccines for COVID-19. She is on the Board of OpGen (OPGN Nasdaq), Aelin Therapeutics and Ocugen (OCGN, Nasdaq). She has authored over 250 publications and several reviews, book chapters and serves as a section editor for Journal of Antibiotics. She obtained her undergraduate and Master’s degree training in India, worked at the University of Ghent, Belgium in Immunochemistry, and received her Ph.D. in Microbiology from Thomas Jefferson University, Philadelphia.
I do not have any relevant financial / non-financial relationships with any proprietary interests.
85 - Public-private Partnerships to Revive Future Antibiotic Development and Access
Friday, October 1, 2021
11:30 AM - 12:45 PM EDT